- Home
- ICUI vs APLS Comparison
ICUI vs APLS Comparison
Compare ICUI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUI
- APLS
- Stock Information
- Founded
- ICUI 1984
- APLS 2009
- Country
- ICUI United States
- APLS United States
- Employees
- ICUI N/A
- APLS N/A
- Industry
- ICUI Medical/Dental Instruments
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- ICUI Health Care
- APLS Health Care
- Exchange
- ICUI Nasdaq
- APLS Nasdaq
- Market Cap
- ICUI 3.8B
- APLS 3.3B
- IPO Year
- ICUI 1992
- APLS 2017
- Fundamental
- Price
- ICUI $141.97
- APLS $25.04
- Analyst Decision
- ICUI Buy
- APLS Buy
- Analyst Count
- ICUI 4
- APLS 18
- Target Price
- ICUI $199.67
- APLS $45.53
- AVG Volume (30 Days)
- ICUI 237.9K
- APLS 1.6M
- Earning Date
- ICUI 05-06-2025
- APLS 02-28-2025
- Dividend Yield
- ICUI N/A
- APLS N/A
- EPS Growth
- ICUI N/A
- APLS N/A
- EPS
- ICUI N/A
- APLS N/A
- Revenue
- ICUI $2,382,046,000.00
- APLS $781,367,000.00
- Revenue This Year
- ICUI N/A
- APLS $12.95
- Revenue Next Year
- ICUI $3.00
- APLS $21.35
- P/E Ratio
- ICUI N/A
- APLS N/A
- Revenue Growth
- ICUI 5.44
- APLS 97.02
- 52 Week Low
- ICUI $93.36
- APLS $23.77
- 52 Week High
- ICUI $196.26
- APLS $63.07
- Technical
- Relative Strength Index (RSI)
- ICUI 31.62
- APLS 35.98
- Support Level
- ICUI $135.77
- APLS $23.77
- Resistance Level
- ICUI $145.58
- APLS $26.15
- Average True Range (ATR)
- ICUI 7.07
- APLS 1.28
- MACD
- ICUI -1.55
- APLS -0.10
- Stochastic Oscillator
- ICUI 21.09
- APLS 24.38
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.